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tamination of the prosthetic graft.3 Similarly, when
the malignancy involves the kidney, staged resection
similar to the approach recommended for the gas-
trointestinal tract can be done, which individualizes
the order of resection according to the size of the
AAA and the stage of the malignant lesion.4
Simultaneous resection may be undertaken in
selected patients. This approach avoids a second
major operative procedure and should not carry an
increased risk of graft contamination, because the
upper urinary tract is often sterile.
Incidental renal neoplasms (RNs) are being
detected with greater frequency because of the
increased use of imaging studies. The management
of small, incidental RNs is still controversial. In most
patients, nephron-sparing surgery (NSS) rather than
radical nephrectomy can be safely performed, espe-
cially in tumors where the largest dimension is less
than or equal to 4 cm.5 In this manner, the loss of
Abdominal aortic aneurysm (AAA) is a disease of
aging. As such, the frequency of AAA increases with
advancing age of the general population.1 Intra-
abdominal malignancies have been found in up to
4% of patients at the time of aortic reconstruction.2
A staged approach is usually preferred in malignan-
cies involving the gastrointestinal tract to avoid con-
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Management of synchronous renal 
neoplasm and abdominal aortic aneurysm
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Objectives: Renal neoplasm (RN) and abdominal aortic aneurysm (AAA) are occasionally
discovered concurrently. The approach to synchronous malignancy and aortic aneurysm
is controversial.
Methods: Between 1981 and 1999, concurrent RN and AAA were diagnosed in 50 patients
at the Cleveland Clinic Foundation. Twenty-three patients were managed conservatively
because of small asymptomatic AAA or metastatic disease; these patients were excluded
from the study. The remaining 27 patients underwent operative management of both
entities with a staged or simultaneous approach, and they form the basis of this article.
Results: AAA diameter ranged from 4.8 to 13 cm (mean, 6.0 ± 1.8 cm). RNs were man-
aged with radical nephrectomy in 11 patients (41%), partial nephrectomy in 10 patients
(37%), or both in 6 patients with bilateral renal tumors (22%). The AAA repair was per-
formed at the time of the urologic procedure in 11 patients (41%), before the urologic
procedure in 13 patients (48%), or after the urologic procedure in 3 patients (11%). The
AAA was addressed with open surgical repair in 24 patients (89%); recently, three patients
(11%) underwent endovascular repair of the aneurysm and staged partial nephrectomy.
The incidence of major perioperative complications was 23% (6 patients). Acute renal fail-
ure was the most common complication (3 [11%]) followed by acute respiratory failure
(2 [7.4%]), pulmonary embolism (1 [3.7%]), and stroke (1 [3.7%]). At the mean follow-
up of 57 months, there were no graft infections reported. The 5-year overall and cancer-
specific survival rates were 62% and 81%, respectively. There was a significant difference
in 5-year cancer-specific survival when comparing patients managed simultaneously ver-
sus staged (80% versus 35%, P =.007).
Conclusions: The concurrent presentation of RN and AAA should not discourage one
from treating both entities simultaneously because long-term survival is common.
Endovascular repair of AAA holds promise as an attractive strategy in these complex
patients. (J Vasc Surg 2000;32:1102-10.)
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renal mass will be minimized in patients with com-
promised renal function, as is sometimes encoun-
tered in patients with aortic disease. The use of
endovascular aortic stenting for the management of
AAA is evolving, with an increased utility of this
technique in the last few years.6 This new modality
holds potential as a solution to the problem of con-
current or closely spaced aneurysm and urologic
procedures. The current study was undertaken to
evaluate our experience in the management of
patients presenting with AAA in association with
renal malignancy.
MATERIAL AND METHODS
From 1981 to 1999, concurrent AAA and RN
were diagnosed in 50 patients at the Cleveland
Clinic Foundation. Patient records were reviewed to
determine the form, size, presentation, manage-
ment, and complications of the AAA and the site,
presentation, pathologic condition, complications,
and management of the renal tumor site. Twenty-
three patients were managed conservatively because
of small, asymptomatic (mean, 4.3 ± 0.9 cm) AAA
or metastatic renal tumor and were excluded from
the study. The remaining 27 patients were treated
surgically and form the basis of this report.
Patient characteristics. Twenty-one aneurysms
were asymptomatic, whereas six patients had symp-
toms from the AAA. RN was considered to be an
“incidental finding” in patients whose diagnostic
evaluation was not initiated by systemic or geni-
tourinary complaints related to the tumor. RN was
diagnosed incidentally in 22 patients, whereas five
patients had hematuria, flank pain, or both.
Patients were evaluated by means of a thorough
physical examination, a complete metabolic panel of
tests including liver function tests, a complete blood
count, a chest radiography, and one or more abdom-
inal imaging studies such as computerized tomo-
graphic (CT) scanning and ultrasound scanning.
Angiography or magnetic resonance imaging was
routinely performed in all patients with AAA and
RN. Recently, three-dimensional spiral abdominal
CT has been found to be helpful in delineating the
details of the renal vasculature, which obviates the
need for angiography in patients undergoing NSS
alone. This approach is being used routinely in our
institute before NSS for renal tumors. Chest CT was
performed in the presence of chest radiography with
abnormal findings. Bone scan was performed if there
were symptoms suggestive of bone metastasis or if
alkaline phosphatase was elevated. Noninvasive car-
diac stress testing, either dobutamine echocardiogra-
phy or the dipyridamol thallium stress test, was
administered to all patients before they underwent
elective surgical procedures.
Surgical treatment. Surgical management of
RN was based on tumor size, location, level of over-
all renal function, and technical feasibility of a
nephron-sparing operation. NSS was performed in
patients with bilateral tumors, patients with solitary
kidney, patients with chronic renal insufficiency, and
patients with general systemic disease who are at risk
of progressive deterioration of renal function. The
management of AAA was determined by the size,
the site, the presentation, the technical feasibility of
open surgical repair versus endovascular stenting,
and the general medical condition of the patient.
Tumor characteristics. Pathologic tumor stag-
ing was determined according to the most recent
TNM system proposed by the International Union
Against Cancer.7 All tumors were measured during
pathologic examination, and tumor size was
reported as the largest dimension of the lesion.
Follow-up. All patients were followed up post-
operatively at 1, 3, 6, and 12 months and once yearly
thereafter; measurements of the serum creatinine
level, chest radiography, and either abdominal
sonography or CT were used in the patients’ evalu-
ation. Postoperative data were obtained by the
review of medical records and, when necessary, by
contacting surviving patients or their local physi-
cians. The mean follow-up period in this series was
57 ± 8 months (range, 6-131).
Statistical analysis. Two-sample t tests were
used to compare all mean values. A Pearson χ2 test
was used to compare all percentages. Kaplan-Meier
survival estimates with log-rank tests were used in all
survival data analysis.
RESULTS
Patient characteristics. Twenty-five patients were
male, and two patients were female. The ages ranged
from 58 to 80 years (mean, 69 ± 5 years). Twenty-
seven patients had their AAA managed operatively.
The AAA size for these patients ranged from 4.8 to
13 cm (mean, 6.0 ± 1.8 cm). The AAA site was
infrarenal in 23 patients and juxtarenal in four
patients. Twenty-four patients had open surgical
repair, and three patients had endovascular repair
(these three patients had staged partial nephrectomy)
and were treated in the last 2 years of the study. Aortic
reconstruction consisted of 5 aortobifemoral bypass
grafts, 9 aortobi-iliac bypass grafts, and 10 tube grafts.
All patients included in this study had localized and
histopathologic-proved renal cell carcinoma (RCC) 
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(n = 26) or transitional cell carcinoma (TCC) (n = 1).
Unilateral tumors were present in 21 patients; six
patients had bilateral RN. Histopathologic examina-
tion of the surgical specimens revealed clear cell carci-
noma in 23 patients, granular and clear cell carcinoma
in 3 patients, and TCC in 1 patient. Seventeen of these
patients had a unifocal lesion, whereas 10 had a multi-
focal tumor. The mean tumor size was 5.7 ± 2.8 cm
(range, 2-15 cm). TNM classification was as follows:
T1a in 7 patients, T1b in 10, T3a in 6, T3b in 3, and
stage T2 TCC in 1. The tumor nuclear grade was I to
II in 14 patients and grade III in 13 patients. There
was neither nodal involvement nor distant metastasis
in any of these patients.
Surgical treatment. The local extent of the renal
tumor was estimated from radiographic and opera-
tive reports. The mean preoperative serum creatinine
level was 1.4 ± 0.4 mg/dL (range, 0.8-2.7 mg/dL).
Radical nephrectomy was used in the management of
10 patients with unilateral RCC. Indications of NSS
(partial nephrectomy) were unilateral RCC in 10
patients (3 with chronic renal insufficiency, 2 with a
solitary kidney, 1 with a horseshoe kidney, 2 with
nephrolithiasis, and 2 with bilateral renal artery dis-
ease, of whom 1 underwent aortorenal bypass graft-
ing). Six patients had bilateral RCC (synchronous in
four and asynchronous in two) and were managed
with a partial nephrectomy on one side and radical
nephrectomy on the contralateral side. One patient
underwent nephroureterectomy for TCC.
Table I. Patient characteristics in both groups
Simultaneous (group 1, n = 11) Staged (group 2, n = 16)
Mean age (y) 70 68
Sex
Male 10 15
Female 1 1
Incidental detection of RN 8 14
Incidental detection of AAA 10 11
Preoperative SCr 1.36 1.34
Radical nephrectomy 5 6
NSS 6 10
Mean follow-up (mo) 40.4 68.5
Tumor size (cm) 5.5 6.8
AAA, Abdominal aortic aneurysm; NSS, nephron-sparing surgery; RN, renal neoplasm, SCr, mean serum creatinine level (mg/dL).
Table II. Tumor characteristics and outcome in both groups
Simultaneous (group 1, n = 11) Staged (group 2, n = 16)
Tumor stage
T1a 1 6
T1b 4 6
T3a 3 3
T3b 3 0 (1 was T2 
TCC)
Tumor grade
I 0 1
II 4 9
III 7 6
Tumor focality
Unifocal 8 9
Multifocal 3 7
5-year survival (%) 80 35
Recurrent RCC 3 5
Outcome
Alive 8 5
Dead metastatic 3 5
Dead NED 0 6
Postoperative SCr 1.9 1.8
NED, No evidence of disease; RCC, renal cell carcinoma; SCr, mean serum creatinine level (mg/dL); TCC, transitional cell carcinoma.
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The AAA repair was performed at the time of the
urologic procedure (11 [41%]), before the urologic
procedure (13 [48%]), or after the urologic procedure
(3 [11%]). The latent period between AAA repair and
the urologic procedure in the staged approach was 97
± 14 days. Of the 11 (41%) patients who underwent
simultaneous procedures, 2 underwent partial
nephrectomy, 5 underwent radical nephrectomy, and
4 underwent a partial nephrectomy on one side and a
radical nephrectomy on the contralateral side.
Hospital course and renal function. The inci-
dence of perioperative complications was 23% (six
patients). Acute renal failure was the most common
complication (3 [11%]), followed by acute respira-
tory failure (2 [7.4%]), deep vein thrombosis and
pulmonary embolism (1 [3.7%]), and stroke (1
[3.7%]). One patient had an intraoperative gallblad-
der injury. The mean preoperative creatinine level
was 1.35 ± 0.46 mg/dL, rising to 1.8 ± 0.7 mg/dL
after both procedures were complete. None of the
patients who underwent NSS had any postoperative
urine leakage or urinoma formation. There are no
aortic graft infections reported to date.
The results of simultaneous (Group 1, n = 11)
versus staged (Group 2, n = 16) surgical approaches
for the management of coexistent AAA and RN were
compared. The characteristics of patients in Groups 1
and 2 are detailed in Table I. There were no signifi-
cant differences between these two groups in terms
of patient age, sex, incidental tumor detection, pre-
operative renal function, AAA presentation, site, sur-
gical approach, or management of RN. The mean
postoperative follow-up for Group 1 versus Group 2
was 40.4 months versus 68.5 months, respectively.
The characteristics of both the AAA and the RN
and the postoperative outcome for Group 1 versus
Fig 1. Overall and cancer-specific survival for patients with AAA coexisting with RN.
Fig 2. Overall survival for patients who underwent simultaneous versus staged approach for AAA coexisting
with RN.
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Group 2 are delineated in Tables I and II. The mean
AAA size for Group 1 and Group 2 was 5.5 cm and
6.8 cm, respectively. The mean tumor size for Group
1 and Group 2 was 5.0 cm and 7.1 cm, respectively.
There was no significant difference in pathologic
tumor stage, type, focality, or grade between the
groups. When simultaneously managed patients were
compared with stage-managed patients, there was no
statistical difference either in the incidence of periop-
erative complications (25% versus 37%) or in the
length of hospital stay (17 ± 11 versus 16 ± 10 days).
There were no aortic graft infections in either group.
Tumor recurrence and patient survival. Re-
current RCC was noted in eight patients. Recurrence
was initially detected locally in one patient in the
remaining portion of the kidney that underwent oper-
ation. Recurrence was manifested in seven patients by
the detection of one or more metastatic lesions with-
out local recurrence. Metastatic disease occurred in
bone (n = 3), lung (n = 2), or both (n = 1), and one
patient had brain metastasis. None of the patients with
pathologic stage T1 had recurrent disease. The fre-
quency of developing metastatic disease was not
increased in patients undergoing staged versus concur-
rent procedures.
At the mean follow-up of 57 months, 13 patients
were alive without evidence of disease and 14
patients died, 8 of whom died with metastatic dis-
ease. The 5-year overall and cancer-specific survival
rates were 62% and 81%, respectively (Fig 1). The 5-
year cancer-specific patient survival rates were 52%
for patients with stage T1 tumors versus 75% for
patients with stage T3 tumors (P > .05). There was a
significant difference in 5-year cancer-specific survival
when comparing patients managed simultaneously
versus staged (80% versus 35%, P = .007) (Fig 2).
DISCUSSION
The widespread use of noninvasive radiologic
studies has led to the discovery of an increasing
number of patients with incidental renal masses.8
Asymptomatic AAAs and renal masses are frequently
discovered during evaluations for other medical
problems. Occasionally, these disease entities present
concomitantly. Both are potentially life threatening
and may require surgical intervention.
Nevertheless, controversy surrounds the man-
agement of concurrent aortic and renal pathologic
conditions because of the following reasons: (1)
there is a potential for aneurysm rupture if surgical
intervention is delayed by staged initial resection of
the malignant lesion, (2) there is a risk of metastasis
if the aneurysm is resected first, and (3) graft conta-
mination is possible if both procedures are per-
formed simultaneously.
The performance of both surgical procedures in
the same setting has the following benefits: (1) The
patient is spared a second major abdominal proce-
dure. (2) The surgical approach for both problems is
similar, either through the peritoneum or the
retroperitoneum. The exposure of the retroperi-
toneum for the aneurysm repair makes simultaneous
left nephrectomy especially attractive; repeat expo-
sure of the retroperitoneum at a second stage is
arduous. (3) The risk of postoperative aneurysm
rupture from activation of proteolytic enzymes is
eliminated.9 Swanson et al10 noted this complication
at a mean of 10 days postoperatively in 10 patients
with a mean AAA diameter of 9.1 cm. Other studies
have shown that the incidence of early postoperative
rupture in patients with AAA who undergo an unre-
lated surgical procedure averages 3%.11
In 1996, Konety et al12 reported the retrospec-
tive results of 10 patients who underwent combined
AAA repair and radical nephrectomy. They com-
pared the outcome with a second group of 10
patients who underwent radical nephrectomy alone
and a third group of 12 patients who had aneurysm
repair alone. There was no significant difference in
outcome among all groups, and, in particular, there
were no graft infections.
Demasi et al13 reported on six patients with
coexisting AAA and RCC. Four patients were
treated simultaneously with nephrectomy and AAA
repair, one was treated with nephrectomy first fol-
lowed by aneurysm repair, and the last patient was
treated conservatively because of metastatic disease.
Two patients died, one of a stroke after a combined
procedure and the other of an unknown cause.
Howe et al14 reviewed their experience with inci-
dental RCC in patients undergoing aortic recon-
struction. Seven of 80 preoperative CT scans
demonstrated suspicious renal lesions (9%). Four
partial and three radical nephrectomies were per-
formed before heparinization and completion of the
planned aortic procedure. The overall mortality rate
was 3%. There was no evidence of local recurrence,
distant metastasis, or graft infection over a mean fol-
low-up of 2 years. The authors recommended explo-
ration of all suspicious renal lesions on the basis of
the incidence of RCC in this patient population (6%)
and concluded that NSS should be considered in
patients with renal insufficiency.
Galt et al15 reported on 10 patients undergoing
simultaneous AAA repair and radical nephrectomy for
RN. Aneurysm repair preceded nephrectomy in seven
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patients. The sequence was reversed in the remaining
three. At a mean follow-up of 2 years, there was no
evidence of graft infection or recurrent disease.
In this study, we present our experience in the
management of patients who were seen with con-
comitant AAA and RN. Twenty-seven patients were
managed surgically. AAA repair was performed at
the time of the urologic procedure in 11 patients
(41%), before the urologic procedure in 13 patients
(48%), or after the urologic procedure in 3 patients
(11%). The 5-year overall and cancer-specific sur-
vival rates were satisfactory, 62% and 81%, respec-
tively. There were no significant differences in the
incidence of complications between staged and
simultaneous approaches, although the long-term
survival was improved in the patients undergoing
simultaneous procedures.
NSS has become a successful form of treatment
for patients with localized RN when there is an
imperative need to preserve functioning renal
parenchyma. This need is present in patients with
bilateral RN, RN involving a solitary functioning
kidney, chronic renal failure, or unilateral RN and a
functioning opposite kidney that is at high risk for
future impairment because of an intercurrent disor-
der. The technical success rate with NSS is excellent,
and long-term patient survival free of cancer is com-
parable to that obtained after radical nephrectomy,
particularly for low-stage RCC.16 The major disad-
vantage of NSS for RN is the risk of local tumor
recurrence in the kidney that underwent operation,
which occurs in 4% to 10% of patients. Some of these
local recurrences may be a manifestation of unde-
tected multifocal RCC in the renal remnant.
Urinary leakage and fistula formation appear to
be the most common complications of NSS.
Campbell et al17 reported an incidence of 17% in
their series. A number of risk factors for urinary fis-
tula formation were identified in this series including
large tumor size (> 4.0 cm), the requirement for a
major reconstruction of the collecting system, and
ex vivo surgery. Central tumor location was also a
risk factor for fistula formation in this series.
Although radical nephrectomy remains the stan-
dard treatment for localized RCC with an anatomi-
cally and functionally normal opposite kidney, a
growing number of authors are reporting excellent
results with NSS in this setting. Clearly, patient selec-
tion on the basis of small tumor size has been a sig-
nificant factor accounting for the favorable outcome
after NSS in these studies. Nevertheless, it is impor-
tant to emphasize that the surgeon’s experience with
NSS must also be considered, and radical nephrec-
tomy should be performed if there is any concern
regarding the ability to completely excise the tumor
with a surrounding margin of normal parenchyma.
In the clinical setting of coexistent RN and AAA,
NSS should only be considered in the presence of
imperative indications (patients with bilateral RN,
RN involving a solitary functioning kidney, chronic
renal insufficiency). Radical nephrectomy should be
the treatment of choice in the presence of an anatom-
ically and functionally normal opposite kidney. In
case of unilateral RN and a functioning opposite kid-
ney that is at high risk for future impairment because
of an intercurrent disorder, NSS should only be con-
sidered in peripheral, small, low-stage tumors with
the collecting system carefully closed with inter-
rupted or continuous sutures to ensure a watertight
closure. Again, the surgeon experience is an impor-
tant contributing factor under these circumstances.
Endovascular exclusion of AAA was first
reported in 1991, and the availability of bifurcated
endografts has broadened the applicability of the
technique. This approach should be considered in
patients with appropriate anatomy as a means of
treating the aneurysm and the renal malignancy in
rapid succession. Endovascular management of the
AAA can be performed first or even concurrently
with either radical or partial nephrectomy for the
management of the renal tumor.
In summary, coexisting AAA and renal masses will
occur in a small proportion of patients. Frequently, the
tumor will be discovered incidentally during CT scan
evaluation of the aneurysm, or occasionally, an
aneurysm will be diagnosed during a hematuria
workup. Factors such as patient age, clinical presenta-
tion (incidental versus symptomatic), AAA size, site
and RCC stage, size, laterality, and presence or absence
of comorbid disease should be considered to guide
therapeutic plans, specifically the sequence and timing
of surgical intervention. A combined approach can be
successfully used in low-risk patients without evidence
of metastatic disease, which would avoid the morbid-
ity and patient discomfort of two major operations.
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reach what Dr O’Donnell talked Friday, that is, “Reductio
Ad Absurdum.” Thank you very much.
Dr Khaled Hafez. Thank you, Dr Ricotta, for the nice
comments. And I’m going to start to address the first ques-
tion, which was the preoperative evaluation for patients
with renal cell cancer. Classically, what we do is a thorough
clinical exam. As far as the labs are concerned, we check the
LFTs and alkaline phosphatase and usually they get a CT
scan of the abdomen with a chest x-ray. If there is any ques-
tion in the chest x-ray, they get a CT scan of the chest. If
the LFTs or alkaline phosphatase is high, and there’s a
question of bone metastases, they get a bone scan.
The second question was, is it going to be difficult to
do a radical nephrectomy followed by an aortic aneurysm.
I don’t think this would be an issue if it’s discovered late
or if the aneurysm was less than 5 cm and there was no
urgent indication to do the repair. I think it could be
delayed for a second procedure. 
The third question addresses the possibilities of urine
leak. Classically doing a radical nephrectomy has no risk of
having urine leaks. There are various techniques to prevent
a leak during the performance of a partial nephrectomy,
depending on the location and size of the tumor. For a
peripheral tumor, meticulous closure of the collecting sys-
tem should be enough. For a centrally located tumor, usu-
ally a double J stent should be placed intraoperatively to
decrease the risk of postoperative leak, in addition, of
course, to clearly close the collecting system meticulously. 
The fourth question about acute renal failure and the
causes and combined approach, I think the reason of the
high incidence of renal failure in these patients was com-
bined for both reduction in renal mass and clamping time
with acute renal failure due to that, too. 
The feeling of attacking both tumors at the same time,
at the timing of the aneurysm, what we’ve been doing
classically in the management of renal cell cancer for bilat-
eral tumors, irrespective of the presence or absence of
aneurysm, is that we usually try to do the partial nephrec-
tomy on one side and stage the radical nephrectomy on
the other side, to keep the patient at least with some pro-
tection from the contralateral kidney. We’ve been doing
some combined bilateral nephrectomies at the same time
with the possibility of not having any clamps on the renal
artery during the procedure. But classically it should be a
staged procedure if it’s an extensive bilateral tumor. 
Your sixth question was about evaluation of different
renal masses. Most solid renal masses are malignancies
with the exception of oncocytomas and angiomyolipomas.
And with a CT scan preoperatively, you should be able to
tell if it has a high fat content, then most likely it’s a
angiomyolipoma. Other than that, most hard tumors
should be evaluated and should be explored, with the
exception of venous cysts, and there’s different classifica-
tions for venous cysts. 
Addressing the question of renal vein involvement.
This depends definitely on the level of the thrombus. If
the thrombus is intrarenal or even onto the vena cava,
which is stage 1, I think it should be safe to address them
both at the same time. If it’s infrahepatic, this would carry
the high risk of more prolonged procedure. But definitely
if it’s suprahepatic, supradiaphragmatic, even reaching the
right atrium, with a possibility of cardiopulmonary circu-
latory arrest, then I think it would be too risky to do them
both at the same time. I think the tumor should be
addressed first and then the aneurysm. 
The reason about late recurrences, it’s well-known for
renal cell cancer to metastasize and recur up to 20 years
after the primary surgery. And this is why it can recur and
this is why the follow-up until now is not very clear for
patients that have been out for 15 years or so. 
The other question about why did we have a difference
in cancer-specific survivor between the staged and the com-
bined group. Until now, the only reason we can think of
right now is that maybe the length of surgery was an issue,
for 3 months or so, to develop metastasis, especially if it’s
an extensive tumor. It’s not very clear if there’s any other
issues concerned. The follow-up in the combined group is
longer than the follow-up in the staged group, too. 
We presented the results about laparoscopic radical
nephrectomy, a partial nephrectomy, at the American
Urological Association a few days ago. We have a series of
100 patients that were performed laparoscopically with a
mean follow-up time of 24 months and with excellent
results, no recurrences until now, and no seedling, and we
felt that laparoscopic nephrectomy in the selected patients,
and these criteria for selection for laparoscopic nephrec-
tomy, depending on tumor stage, tumor size, definitely
presence or absence of renal vein involvement. For the
time being I think it could be with a future questionable
possibility to perform laparoscopic surgery on endograft
fixation of the abdominal aortic aneurysm. Thanks a lot. 
Dr Mark B. Kahn (Philadelphia, Pa). I think the issue
is what is an acceptable leak rate if the patient opts for a
nephron-sparing nephrectomy? Because there really, as
you stated, isn’t much downside, if the patient is stable
after you fix your aneurysm. There isn’t much downside to
clipping the ureter and ligating the renal vessels and doing
the radical nephrectomy. So I’m curious as to what your
leak rate is and what you would consider an acceptable
leak rate in the face of a new retroperitoneal graft. 
Dr Hafez. The acceptable leak rate for a partial
nephrectomy, of course, depends on the size of the tumor
and the location of the tumor. But we send patients home
with a retroperitoneal drain and a leak between 200 cc and
400 cc every day. This is for partial nephrectomies not
with aneurysm. 
With an aneurysm, I think it’s definitely a higher risk.
And putting in mind that this urine leak could be most
probably a sterile leak, we would accept 200 cc to be sent
home with a retroperitoneal drain. 
Dr Kahn. When it’s leaking the 200 cc a day, where is
it leaking to? 
Dr Hafez. It leaks into the retroperitoneum, and it’s
drained outside. 
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Dr Kahn. So is that a source of infection? 
Dr Hafez. It could be definitely a source of infection. I
think what we should do in this patient population, these
should be followed meticulously. And if we found that this
thing is not improving and it’s getting worse, a double J
stent should be placed as an outpatient procedure easily. 
Dr Kahn. Well, I guess what I’m wondering is, should
partial nephrectomy be offered with an increased risk of
infection when you’re putting in an aortic graft? 
Dr Hafez. I think it should be offered with being more
meticulous during closure and putting a double J stent
preoperatively even if you would like.
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